良性前列腺增生

Lee SW, Chan EM, Lai YK. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. Sci Rep. 2017 Aug 11;7(1):7984.

• 全文
• 摘要

Patel AK, Chapple CR. Benign prostatic hyperplasia: treatment in primary care. BMJ. 2006 Sep 9;333(7567):535-9.

• 摘要

American Urological Association. American Urological Association guideline: management of benign prostatic hyperplasia (BPH). 2010; re-affirmed 2014 [internet publication].

• 全文

European Association of Urology. Treatment of non-neurogenic male LUTS. 2018 [internet publication].

• 全文

McConnell JD, Roehrborn CG, Bautista O, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003 Dec 18;349(25):2387-98.

• 摘要

Gacci M, Sebastianelli A, Spatafora P, et al. Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base. Ther Adv Urol. 2017 Dec 7;10(2):79-92.

• 全文
• 摘要

American Urological Association. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia. May 2018 [internet publication].

• 全文

Andriole GL, Bostwick DG, Brawley OW, et al; REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010 Apr 1;362(13):1192-202.

• 全文
• 摘要

1.  Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am. 2016 Aug;43(3):289-97.

• 摘要

2.  Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol. 1984 Sep;132(3):474-9.

• 摘要

3.  US Census Bureau. 65+ in the United States. Apr 1996 [internet publication].

• 全文

4.  Masumori N, Tsukamoto T, Kumamoto Y, et al. Japanese men have smaller prostate volumes but comparable urinary flow rates relative to American men: results of community based studies in 2 countries. J Urol. 1996 Apr;155(4):1324-7.

• 摘要

5.  Lee SW, Chan EM, Lai YK. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. Sci Rep. 2017 Aug 11;7(1):7984.

• 全文
• 摘要

6.  Bosch JL, Hop WC, Kirkels WJ, et al. Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology. 1995 Sep;46(3 Suppl A):34-40.

• 摘要

7.  Rosenberg MT, Miner MM, Riley PA, et al. STEP: simplified treatment of the enlarged prostate. Int J Clin Pract. 2010 Mar;64(4):488-96.

• 摘要

8.  Speakman M, Kirby R, Doyle S, et al. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK. BJU Int. 2015 Apr;115(4):508-19.

• 全文
• 摘要

9.  Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate. 1989;15(S2):33-50.

• 摘要

10.  Patel AK, Chapple CR. Benign prostatic hyperplasia: treatment in primary care. BMJ. 2006 Sep 9;333(7567):535-9.

• 摘要

11.  Partin AW, Page WF, Lee BR, et al. Concordance rates for benign prostatic disease among twins suggest hereditary influence. Urology. 1994 Nov;44(5):646-50.

• 摘要

12.  Cabelin MA, Te AE, Kaplan SA. Benign prostatic hyperplasia: challenges for the new millennium. Curr Opin Urol. 2000 Jul;10(4):301-6.

• 摘要

13.  Ziada A, Rosenblum M, Crawford ED. Benign prostatic hyperplasia: an overview. Urology. 1999 Mar;53(3 Suppl 3a):1-6.

• 摘要

14.  Kasturi S, Russell S, McVary KT. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep. 2006 Jul;7(4):288-92.

• 摘要

15.  Parsons JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol. 2007 Aug;178(2):395-401.

• 摘要

16.  American Urological Association. American Urological Association guideline: management of benign prostatic hyperplasia (BPH). 2010; re-affirmed 2014 [internet publication].

• 全文

17.  Schröder FH, Hugosson J, Roobol MJ, et al; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009 Mar 26;360(13):1320-8.

• 全文
• 摘要

18.  Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009 Mar 26;360(13):1310-9.

• 全文
• 摘要

19.  European Association of Urology. Treatment of non-neurogenic male LUTS. 2018 [internet publication].

• 全文

20.  El-Zawahry A, Alanee S, Malan-Elzawahry A. The use of urodynamics assessment before the surgical treatment of BPH. Curr Urol Rep. 2016 Oct;17(10):73.

• 摘要

21.  McConnell JD. Benign prostatic hyperplasia: treatment guidelines and patient classification. Br J Urol. 1995 Jul;76 Suppl 1:29-46.

• 摘要

22.  O'Leary MP. Validity of the "bother score" in the evaluation and treatment of symptomatic benign prostatic hyperplasia. Rev Urol. 2005 Winter;7(1):1-10.

• 全文
• 摘要

23.  Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 1999;36(1):1-13.

• 摘要

24.  Fusco F, Palmieri A, Ficarra V, et al. Alpha1-blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review and meta-analysis of urodynamic studies. Eur Urol. 2016 Jun;69(6):1091-101.

• 摘要

25.  Welk B, McArthur E, Fraser LA, et al. The risk of fall and fracture with the initiation of a prostate-selective alpha antagonist: a population based cohort study. BMJ. 2015 Oct 26;351:h5398.

• 全文
• 摘要

26.  Russo A, Hedlund P, Montorsi F. Silodosin from bench to bedside: selectivity, safety, and sustained efficacy. Eur Urol Suppl. 2011 Oct;10(6):445-50.

• 全文

27.  Jung JH, Kim J, MacDonald R, et al. Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev. 2017 Nov 22;(11):CD012615.

• 全文
• 摘要

28.  McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998 Feb 26;338(9):557-63.

• 摘要

29.  Marberger MJ; The PROWESS Study Group. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. Urology. 1998 May;51(5):677-86.

• 摘要

30.  McNicholas T, Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid. 2011 Aug 26;2011:1801.

• 全文
• 摘要

31.  Kaplan SA, Lee JY, Meehan AG, et al. Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. J Urol. 2011 Apr;185(4):1369-73.

• 摘要

32.  Barkin J, Roehrborn CG, Siami P, et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int. 2009 Apr;103(7):919-26.

• 摘要

33.  McConnell JD, Roehrborn CG, Bautista O, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003 Dec 18;349(25):2387-98.

• 摘要

34.  Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010 Jan;57(1):123-31. [Erratum in: Eur Urol. 2010 Nov;58(5):801.]

• 摘要

35.  Roehrborn CG, Siami P, Barkin J, et al; CombAT Study Group. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008 Feb;179(2):616-21.

• 摘要

36.  Liu L, Zheng S, Han P, et al. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. Urology. 2011 Jan;77(1):123-9.

• 摘要

37.  Laydner HK, Oliveira P, Oliveira CR, et al. Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review. BJU Int. 2011 Apr;107(7):1104-9.

• 摘要

38.  Gacci M, Andersson KE, Chapple C, et al. Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2016 Jul;70(1):124-33.

• 摘要

39.  Gacci M, Corona G, Salvi M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012 May;61(5):994-1003.

• 全文
• 摘要

40.  Gacci M, Novara G, De Nunzio C, et al. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review. BMC Urol. 2014 Oct 27;(14):84.

• 全文
• 摘要

41.  Gacci M, Sebastianelli A, Spatafora P, et al. Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base. Ther Adv Urol. 2017 Dec 7;10(2):79-92.

• 全文
• 摘要

42.  Kim HJ, Sun HY, Choi H, et al. Efficacy and safety of initial combination treatment of an alpha blocker with an anticholinergic medication in benign prostatic hyperplasia patients with lower urinary tract symptoms: updated meta-analysis. PLoS One. 2017 Jan 10;12(1):e0169248.

• 全文
• 摘要

43.  American Urological Association. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia. May 2018 [internet publication].

• 全文

44.  Hoffman RM, Monga M, Elliott SP, et al. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD004135.

• 全文
• 摘要

45.  Bouza C, López T, Magro A, et al. Systematic review and meta-analysis of Transurethral Needle Ablation in symptomatic Benign Prostatic Hyperplasia. BMC Urol. 2006 Jun 21;6:14.

• 全文
• 摘要

46.  Roehrborn CG, Gange SN, Shore ND, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J Urol. 2013 Dec;190(6):2161-7.

• 摘要

47.  da Silva RD, Bidikov L, Michaels W, et al. Bipolar energy in the treatment of benign prostatic hyperplasia: a current systematic review of the literature. Can J Urol. 2015 Oct;22(suppl 1):30-44.

• 全文
• 摘要

48.  Nuhoğlu B, Balci MB, Aydin M, et al. The role of bipolar transurethral vaporization in the management of benign prostatic hyperplasia. Urol Int. 2011;87(4):400-4.

• 摘要

49.  Fowler C, McAllister W, Plail R, et al. Randomised evaluation of alternative electrosurgical modalities to treat bladder outflow obstruction in men with benign prostatic hyperplasia. Health Technol Assess. 2005 Feb;9(4):iii-iv, 1-30.

• 全文
• 摘要

50.  Cornu JN, Ahyai S, Bachmann A, et al. A systematic review and meta-analysis of functional outcomes and complications rollowing transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol. 2015 Jun;67(6):1066-96.

• 摘要

51.  Zang YC, Deng XX, Yang DR, et al. Photoselective vaporization of the prostate with GreenLight 120-W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review with meta-analysis of randomized controlled trials. Lasers Med Sci. 2016 Feb;31(2):235-40.

• 摘要

52.  Kang DH, Cho KS, Ham WS, et al. A systematic review and meta-analysis of functional outcomes and complications following the photoselective vaporization of the prostate and monopolar transurethral resection of the prostate. World J Mens Health. 2016 Aug;34(2):110-22.

• 全文
• 摘要

53.  Thomas JA, Tubaro A, Barber N, et al. A multicenter randomized noninferiority trial comparing GreenLight-XPS laser vaporization of the prostate and transurethral resection of the prostate for the treatment of benign prostatic obstruction: two-yr outcomes of the GOLIATH study. Eur Urol. 2016 Jan;69(1):94-102.

• 摘要

54.  Li S, Zeng XT, Ruan XL, et al. Holmium laser enucleation versus transurethral resection in patients with benign prostate hyperplasia: an updated systematic review with meta-analysis and trial sequential analysis. PLoS One. 2014 Jul 8;9(7):e101615.

• 全文
• 摘要

55.  Jiang H, Zhou Y. Safety and efficacy of thulium laser prostatectomy versus transurethral resection of prostate for treatment of benign prostate hyperplasia: a meta-analysis. Low Urin Tract Symptoms. 2016 Sep;8(3):165-70.

• 摘要

56.  Skinner TA, Leslie RJ, Steele SS, et al. Randomized, controlled trial of laser vs. bipolar plasma vaporization treatment of benign prostatic hyperplasia. Can Urol Assoc J. 2017 Jun;11(6):194-8.

• 全文
• 摘要

57.  Albisinni S, Aoun F, Roumeguère T, et al. New treatment strategies for benign prostatic hyperplasia in the frail elderly population: a systematic review. Minerva Urol Nefrol. 2017 Apr;69(2):119-32.

• 全文
• 摘要

58.  Li M, Qiu J, Hou Q, et al. Endoscopic enucleation versus open prostatectomy for treating large benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. PLoS One. 2015 Mar 31;10(3):e0121265.

• 全文
• 摘要

59.  Hahn RG. The transurethral resection syndrome. Acta Anaesthesiol Scand. 1991 Oct;35(7):557-67.

• 摘要

60.  Marks LS, Gittelman MC, Hill LA, et al. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. Urology. 2009 Jun;181(6):2634-40.

• 摘要

61.  Ding H, Du W, Hou ZZ, et al. Silodosin is effective for treatment of LUTS in men with BPH: a systematic review. Asian J Androl. 2013 Jan;15(1):121-8.

• 全文
• 摘要

62.  Marks LS, Gittelman MC, Hill LA, et al. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2013 Jan;189(1 Suppl):S122-8.

• 全文
• 摘要

63.  Andriole GL, Bostwick DG, Brawley OW, et al; REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010 Apr 1;362(13):1192-202.

• 全文
• 摘要

64.  Dmochowski R, Roehrborn C, Klise S, et al. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol. 2010 Mar;183(3):1092-7.

• 摘要

65.  Broderick GA, Brock GB, Roehrborn CG, et al. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology. 2010 Jun;75(6):1452-8.

• 摘要

66.  Tacklind J, Fink HA, Macdonald R, et al. Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2010 Oct 6;(10):CD006015.

• 摘要

67.  Haillot O, Fraga A, Maciukiewicz P, et al. The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study. Prostate Cancer Prostatic Dis. 2011 Dec;14(4):302-6.

• 摘要

68.  European Association of Urology. Treatment of non-neurogenic male LUTS. 2018 [internet publication].

• 全文

69.  Wang XY, Zong HT, Zhang Y. Efficacy and safety of prostate artery embolization on lower urinary tract symptoms related to benign prostatic hyperplasia: a systematic review and meta-analysis. Clin Interv Aging. 2016 Nov 11;11:1609-22.

• 摘要

70.  Abt D, Hechelhammer L, Müllhaupt G, et al. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ. 2018 Jun 19;361:k2338.

• 全文
• 摘要

71.  Kuang M, Vu A, Athreya S. A systematic review of prostatic artery embolization in the treatment of symptomatic benign prostatic hyperplasia. Cardiovasc Intervent Radiol. 2017 May;40(5):655-63.

• 摘要

72.  Pyo JS, Cho WJ. Systematic review and meta-analysis of prostatic artery embolisation for lower urinary tract symptoms related to benign prostatic hyperplasia. Clin Radiol. 2017 Jan;72(1):16-22.

• 摘要

73.  Feng S, Tian Y, Liu W, et al. Prostatic arterial embolization treating moderate-to-severe lower urinary tract symptoms related to benign prostate hyperplasia: a meta-analysis. Cardiovasc Intervent Radiol. 2017 Jan;40(1):22-32.

• 摘要

74.  Cizman Z, Isaacson A, Burke C. Short- to midterm safety and efficacy of prostatic artery embolization: a systematic review. J Vasc Interv Radiol. 2016 Oct;27(10):1487-93.e1.

• 摘要

75.  Shore N, Tutrone R, Efros M, et al. Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement. World J Urol. 2018 May;36(5):801-9.

• 全文
• 摘要

76.  Gjertson CK, Walmsley K, Kaplan SA. Benign prostatic hyperplasia: now we can begin to tailor treatment. Cleve Clin J Med. 2004 Nov;71(11):857, 860, 863-5.

• 摘要

77.  Yokoyama T, Kumon H, Nasu Y, et al. Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study. Int J Urol. 2006 Jul;13(7):932-8.

• 摘要

78.  Gotoh M, Kamihira O, Kinukawa T, et al. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. BJU Int. 2005 Sep;96(4):581-6.

• 摘要

79.  Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006 Feb 9;354(6):557-66.

• 全文
• 摘要

80.  Barry MJ, Meleth S, Lee JY, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA. 2011 Sep 28;306(12):1344-51.

• 全文
• 摘要

81.  Crawford-Faucher A. Saw palmetto extract ineffective for BPH symptoms. Am Fam Physician. 2012 Jun 15;85(12):1202.

• 全文

82.  Miner M, Rosenbert MT, Perelman MA. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Clin Ther. 2006 Jan;28(1):13-25.

• 摘要

83.  Kuritzky L. Noninvasive management of lower urinary tract symptoms and sexual dysfunction associated with benign prostatic hyperplasia in the primary care setting. Com Ther. 2005 Fall;31(3):194-208.

• 摘要

84.  Dijk V, Marleen M, Rosette DL, et al. Effects of alpha (1)-adrenoceptor antagonists on male sexual function. Drugs. 2006;66(3):287-301.

• 摘要

85.  Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int. 2006 Apr;97 Suppl 2:34-8.

• 全文
• 摘要

86.  Yanardag H, Goktas S, Kibar Y, et al. Intermittent tamsulosin therapy in men with lower urinary tract symptoms. J Urol. 2005 Jan;173(1):155-7.

• 摘要

87.  Kobayashi M, Tokue A, Morita T. Discontinuation of tamsulosin treatment in men with lower urinary tract symptoms: a pilot study. Urol Inter. 2006;76(4):304-8.

• 摘要

88.  Chung BH, Lee SH, Roehrborn CG, et al. Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: long-term results from the combination of dutasteride and tamsulosin study. Int J Urol. 2012 Nov;19(11):1031-5.

• 全文
• 摘要

89.  Kaplan SA, Roehrborn CG, Gong J, et al. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving alpha-blocker treatment for lower urinary tract symptoms. BJU Int. 2012 Jun;109(12):1831-40.

• 摘要